-
Esperion Therapeutics Inc (NASDAQ: ESPR) shares
climbed 49.3 percent to $35.34 after the company reported the FDA confirmation regarding regulatory pathway to approval for an
LDL-C lowering indication for bempedoic acid.
-
Bellerophon Therapeutics Inc (NASDAQ: BLPH)
shares surged 35.4 percent to $1.39.
-
Nektar Therapeutics (NASDAQ: NKTR) shares jumped
34.2 percent to $20.80 after the company reported that it has achieved primary and secondary endpoints in Phase 3 SUMMIT-07
study.
-
CytomX Therapeutics Inc (NASDAQ: CTMX) climbed
23.5 percent to $18.74. Bristol-Myers Squibb Co (NYSE: BMY) and CytomX Therapeutics disclosed that they have extended worldwide
partnership to discover Probody therapeutics for the treatment of cancer and other diseases.
-
Dominion Diamond Corp (NYSE: DDC) shares surged 22.6
percent to $12.16. The Washington Companies proposed to acquire Dominion Diamond for US$13.50 per share in cash.
-
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares
jumped 17.5 percent to $9.05. Aurinia Pharmaceuticals shares have climbed 148.39 percent over the past 52 weeks, while the
S&P 500 index has gained 15.92 percent in the same period.
-
ContraVir Pharmaceuticals Inc (NASDAQ: CTRV)
shares gained 16.6 percent to $1.69.
-
Omeros Corporation (NASDAQ: OMER) shares surged
11.2 percent to $11.72.
-
FireEye Inc (NASDAQ: FEYE) shares climbed 8.6
percent to $11.65. Bank of America upgraded FireEye from Neutral to Buy.
-
Aralez Pharmaceuticals Inc (NASDAQ: ARLZ) gained
7.1 percent to $2.41 after the company disclosed that its CEO has purchased 500,000 open market shares at an average price of
$2.46 per share.
-
American Railcar Industries, Inc. (NASDAQ: ARII)
rose 7.1 percent to $42.71. Cowen & Co. upgraded American Railcar from Market Perform to Outperform.
-
MeetMe Inc (NASDAQ: MEET) shares surged 4.8
percent to $5.44. Canaccord Genuity initiated coverage on MeetMe with a Buy rating.
Latest Ratings for ESPR
Date |
Firm |
Action |
From |
To |
Mar 2017 |
Credit Suisse |
Upgrades |
Underperform |
Neutral |
Feb 2017 |
Citigroup |
Upgrades |
Neutral |
Buy |
Nov 2016 |
Citigroup |
Downgrades |
Buy |
Neutral |
View More Analyst Ratings for
ESPR
View the Latest Analyst Ratings
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.